blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1470220

EP1470220 - SELECTIVE ENZYMATIC ESTERIFICATION AND SOLVOLYSIS OF EPIMERIC VITAMIN D ANALOG AND SEPARATION OF THE EPIMERS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.08.2012
Database last updated on 13.09.2024
Most recent event   Tooltip18.07.2014Lapse of the patent in a contracting state
New state(s): HU		published on 20.08.2014  [2014/34]
Applicant(s)For all designated states
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
5 Basel Street, P.O. Box 3190
49131 Petah Tiqva / IL
[N/P]
Former [2004/44]For all designated states
TEVA PHARMACEUTICAL INDUSTRIES LTD.
5 Basel Street, P.O. Box 3190
49131 Petah Tiqva / IL
Inventor(s)01 / SHAPIRO, Evgeny
18/1 Gut Levin St.
32922 Haifa / IL
02 / FISHMAN, Ayelet
25 Beilis St.
34814 Haifa / IL
03 / EFFENBERGER, Reinhard
17 Harofeh St.
34367 Haifa / IL
04 / MAYMON, Asher
79 Menachem Begin St.
49732 Petach Tikva / IL
05 / SCHWARTZ, Anchel
Aharoni 11/9
Rehovot 76281 / IL
 [2004/44]
Representative(s)Gallagher, Kirk James, et al
D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
[N/P]
Former [2011/50]Gallagher, Kirk James, et al
D Young & Co LLP 120 Holborn
London EC1N 2DY / GB
Former [2004/44]Bradley, Josephine Mary, et al
D. Young & Co., 21 New Fetter Lane
London EC4A 1DA / GB
Application number, filing date03729607.609.01.2003
[2004/44]
WO2003US00623
Priority number, dateUS20020348082P10.01.2002         Original published format: US 348082 P
US20020349977P18.01.2002         Original published format: US 349977 P
[2004/44]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO03060094
Date:24.07.2003
Language:EN
[2003/30]
Type: A2 Application without search report 
No.:EP1470220
Date:27.10.2004
Language:EN
The application published by WIPO in one of the EPO official languages on 24.07.2003 takes the place of the publication of the European patent application.
[2004/44]
Type: B1 Patent specification 
No.:EP1470220
Date:05.10.2011
Language:EN
[2011/40]
Search report(s)International search report - published on:US24.12.2003
(Supplementary) European search report - dispatched on:EP06.11.2007
ClassificationIPC:C12P41/00
[2007/49]
CPC:
C12P7/18 (EP,US); C12P7/62 (KR); C12N9/0004 (KR);
C12P41/004 (EP,US)
Former IPC [2004/44]C12N9/20
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   SI,   SK,   TR [2004/44]
Extension statesRO21.07.2004
TitleGerman:SELEKTIVE ENZYMATISCHE VERESTERUNG UND SOLVOLYSE EINES EPIMEREN VITAMIN-D-ANALOGS SOWIE TRENNUNG DER EPIMERE[2004/44]
English:SELECTIVE ENZYMATIC ESTERIFICATION AND SOLVOLYSIS OF EPIMERIC VITAMIN D ANALOG AND SEPARATION OF THE EPIMERS[2004/44]
French:ESTERIFICATION ET SOLVOLYSE ENZYMATIQUES SELECTIVES D'UN ANALOGUE EPIMERIQUE DE LA VITAMINE D ET SEPARATION DES EPIMERES[2004/44]
Entry into regional phase21.07.2004National basic fee paid 
21.07.2004Search fee paid 
21.07.2004Designation fee(s) paid 
21.07.2004Examination fee paid 
Examination procedure08.08.2003Request for preliminary examination filed
International Preliminary Examining Authority: US
20.07.2004Amendment by applicant (claims and/or description)
21.07.2004Examination requested  [2004/44]
27.03.2008Despatch of a communication from the examining division (Time limit: M06)
06.10.2008Reply to a communication from the examining division
14.01.2009Despatch of a communication from the examining division (Time limit: M04)
21.05.2009Reply to a communication from the examining division
22.06.2009Despatch of a communication from the examining division (Time limit: M04)
26.08.2009Reply to a communication from the examining division
14.04.2011Communication of intention to grant the patent
10.08.2011Fee for grant paid
10.08.2011Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  27.03.2008
Opposition(s)06.07.2012No opposition filed within time limit [2012/37]
Fees paidRenewal fee
07.01.2005Renewal fee patent year 03
19.01.2006Renewal fee patent year 04
11.01.2007Renewal fee patent year 05
14.01.2008Renewal fee patent year 06
25.03.2008Renewal fee patent year 07
22.01.2010Renewal fee patent year 08
24.01.2011Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU09.01.2003
AT05.10.2011
BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
FI05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
TR05.10.2011
BG05.01.2012
GR06.01.2012
IE09.01.2012
LU09.01.2012
CH31.01.2012
LI31.01.2012
MC31.01.2012
PT06.02.2012
[2014/34]
Former [2014/27]AT05.10.2011
BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
FI05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
TR05.10.2011
BG05.01.2012
GR06.01.2012
IE09.01.2012
LU09.01.2012
CH31.01.2012
LI31.01.2012
MC31.01.2012
PT06.02.2012
Former [2014/21]AT05.10.2011
BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
FI05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
TR05.10.2011
BG05.01.2012
GR06.01.2012
IE09.01.2012
CH31.01.2012
LI31.01.2012
MC31.01.2012
PT06.02.2012
Former [2013/29]AT05.10.2011
BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
FI05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
BG05.01.2012
GR06.01.2012
IE09.01.2012
CH31.01.2012
LI31.01.2012
MC31.01.2012
PT06.02.2012
Former [2013/08]AT05.10.2011
BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
GR06.01.2012
IE09.01.2012
CH31.01.2012
LI31.01.2012
MC31.01.2012
PT06.02.2012
Former [2013/07]AT05.10.2011
BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
GR06.01.2012
CH31.01.2012
LI31.01.2012
MC31.01.2012
PT06.02.2012
Former [2012/49]BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
GR06.01.2012
CH31.01.2012
LI31.01.2012
MC31.01.2012
PT06.02.2012
Former [2012/37]BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
GR06.01.2012
MC31.01.2012
PT06.02.2012
Former [2012/36]BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
GR06.01.2012
PT06.02.2012
Former [2012/35]BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
SE05.10.2011
SI05.10.2011
GR06.01.2012
PT06.02.2012
Former [2012/34]BE05.10.2011
CY05.10.2011
CZ05.10.2011
SE05.10.2011
SI05.10.2011
GR06.01.2012
PT06.02.2012
Former [2012/28]BE05.10.2011
CY05.10.2011
SE05.10.2011
SI05.10.2011
GR06.01.2012
PT06.02.2012
Former [2012/24]BE05.10.2011
SE05.10.2011
SI05.10.2011
GR06.01.2012
PT06.02.2012
Former [2012/23]BE05.10.2011
SI05.10.2011
GR06.01.2012
PT06.02.2012
Former [2012/21]BE05.10.2011
SI05.10.2011
Former [2012/11]SI05.10.2011
Documents cited:Search[A]WO8700834  (LEO PHARM PROD LTD [DK]) [A] 1-40 * Abstract; Formula I. *;
 [A]US5637500  (SIH CHARLES J [US]) [A] 1,11,29,30,32,33 * Abstract; claim 1, examples, col. 4, l. 35-40. *;
 [A]WO0061777  (CHIROTECH TECHNOLOGY LTD [GB]) [A] 1,11,29,30,32,33 * Abstract; claim 1, examples, p. 6, l. 1-9, p. 7, l. 18-20. *;
 [A]WO0190396  (DSM NV [NL], et al) [A] 1,11,29,30,32,33 * Abstract; claim 1, examples. *;
 [E]WO03106412  (TEVA PHARMA [IL], et al) [E] 1-40* Abstract; claim 1, examples 9, 13 and 14. *;
 [DA]  - CALVERLEY M J, "SYNTHESIS OF MC 903, A BIOLOGICALLY ACTIVE VITAMIN D METABOLITE ANALOGUE", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, (1987), vol. 43, no. 20, ISSN 0040-4020, pages 4609 - 4619, XP001147723 [DA] 1-40 * Abstract; compounds 1-29. *

DOI:   http://dx.doi.org/10.1016/S0040-4020(01)86903-9
 [A]  - CALVERLEY M J ET AL, "1-alpha-24S-dihydroxy-26,27-cyclo-22-yne-vitamin D3: the side chain triple bond analogue of MC 903 (calcipotriol)", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, (1993), vol. 3, no. 9, ISSN 0960-894X, pages 1841 - 1844, XP002273655 [A] 1-40 * Abstract, compounds 1-13. *

DOI:   http://dx.doi.org/10.1016/S0960-894X(00)80116-X
International search[A]US5665716  (KIRSCH GERALD DR [DE], et al)
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.